View Article Online View Journal



Organic & Biomolecular Chemistry

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: H. Fu, S. Younes, M. Saifuddin, P. Tepper, J. Zhang, E. Keller, A. Heeres, W. Szymanski and G. J. Poelarends, *Org. Biomol. Chem.*, 2017, DOI: 10.1039/C7OB00305F.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the **author guidelines**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the ethical guidelines, outlined in our <u>author and reviewer resource centre</u>, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.



rsc.li/obc

Rapid Chemoenzymatic Route to Glutamate Transporter Inhibitor L-TFB-TBOA and Related Amino Acids

Haigen Fu,^[a] Sabry H. H. Younes,^[a] Mohammad Saifuddin,^[a] Pieter G. Tepper,^[a]

Jielin Zhang,^[a] Erik Keller,^[b] André Heeres,^[b] Wiktor Szymanski,^[c] and

Gerrit J. Poelarends*[a]

[a] H. Fu,⁺ Dr. S. H. H. Younes,⁺ Dr. M. Saifuddin, P. G. Tepper, J. Zhang, Prof.
 Dr. G. J. Poelarends

Department of Chemical and Pharmaceutical Biology,

Groningen Research Institute of Pharmacy, University of Groningen,

Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands

E-mail: g.j.poelarends@rug.nl

Homepage: http://www.rug.nl/staff/g.j.poelarends/

[b] Dr. E. Keller, Dr. A. Heeres

Syncom BV, Kadijk 3, 9747 AT Groningen, The Netherlands

[c] Dr. W. Szymanski

Department of Radiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

[+] These authors contributed equally to this work.

Organic & Biomolecular Chemistry Accepted Manuscript

Abstract

View Article Online DOI: 10.1039/C7OB00305F

The complex amino acid (L-*threo*)-3-[3-[4-(trifluoromethyl)benzoylamino] benzyloxy]aspartate (L-TFB-TBOA) and its derivatives are privileged compounds for studying the roles of excitatory amino acid transporters (EAATs) in regulation of glutamatergic neurotransmission, animal behavior, and in the pathogenesis of neurological diseases. The wide-spread use of L-TFB-TBOA stems from its high potency of EAAT inhibition and the lack of off-target binding to glutamate receptors. However, one of the main challenges in the evaluation of L-TFB-TBOA and its derivatives is the laborious synthesis of these compounds in stereoisomerically pure form. Here, we report an efficient and step-economic chemoenzymatic route that gives access to enantio- and diastereopure L-TFB-TBOA and its derivatives at multigram scale.

Introduction

Organic & Biomolecular Chemistry Accepted Manuscript

L-Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system (CNS) and mediates numerous neuronal communications in the brain.¹ However, accumulation of high levels of extracellular glutamate may lead to over-activation of glutamate-gated ion channels and, consequently, neuronal injury.² Synaptic glutamate concentrations are strictly kept below levels of neurotoxicity by the family of excitatory amino acid transporters (EAATs) expressed on neurons and surrounding glial cells.³ Dysfunction of EAATs has been implicated in many neurological disorders, such as Alzheimer's disease, epilepsy, amyotrophic lateral sclerosis, and Huntington's disease.⁴

L-Aspartate derivatives with anyloxy substituents at the C3 position, exemplified by L-threo-3-benzyloxyaspartate (1, L-TBOA, Scheme 1), were identified as the first class of nontransportable EAAT inhibitors.⁵ The importance of these L-aspartate derivatives as tools in neurobiological research was further highlighted by the identification of the widely used blocker. most potent and (L-threo)-3-[3-[4-(trifluoromethyl)benzoylamino]benzyloxy]aspartate (2a,L-TFB-TBOA, Scheme 1), which has nanomolar affinity to EAAT1 and EAAT2 and lacks affinity towards other glutamate receptors and transporters.⁶ However, the asymmetric synthesis of enantiopure L-TFB-TBOA and related compounds proved to be extremely challenging. Shimamoto and coworkers reported the asymmetric synthesis of enantiopure 2a through an elaborate 20-step synthetic procedure.⁷ Although a concise synthesis of 2a based on Sharpless aminohydroxylation with

Organic & Biomolecular Chemistry Accepted Manuscript

View Article Online

chiral ligand (DHQD)₂PHAL was recently reported by Leuenberger et al., this procedure provided **2a** with only 40% enantiomeric excess (*ee*).⁸ Efficient asymmetric synthesis of enantiopure L-TFB-TBOA and its derivatives would facilitate the further discovery of EAAT subtype-selective inhibitors, which are highly useful tools for the elucidation of the exact physiological roles of distinct EAATs in glutamate accumulation⁹, synaptic transmission^{6c} and animal behavior^{6a}. Hence, alternative procedures that provide efficient and more step-economic access to 2a and related compounds are in great demand. Herein, we report a rapid chemoenzymatic route that gives convenient access to enantiopure L-TFB-TBOA and its derivatives at multigram scale. This method uses the late functionalization of a common precursor to provide a convenient way of divergent preparation of L-aspartate derivatives with large aryloxy substituents at the C3 position (Scheme 1).

Results and Discussion

Retrosynthetic analysis suggests that L-TFB-TBOA (2a) could be derived from dimethyl (L-threo)-N-Boc-3-hydroxyaspartate (4) and substituted benzyl bromide 5a via O-alkylation and subsequent deprotection (Scheme 1). The key challenge was the formation of chiral building block 4 due to the possible difficulties in constructing the required L-threo configuration at vicinal chiral centers with a 1,2-aminoalcohol motif.¹⁰ We envisioned that this key precursor **4** could be readily generated from **1**, which has the desired L-threo configuration, via protection and hydrogenolysis steps. While the chemical synthesis of **1** is a highly challenging 11-step procedure, 5^{c} a

Organic & Biomolecular Chemistry

View Article Online

straightforward three-step chemoenzymatic methodology for the asymmetric synthesis

of 1 (de >99%, ee >99%), starting from commercially available dimethyl acetylenedicarboxylate **3**, has recently been reported (Scheme 2A).¹¹



Scheme 1. Chemoenzymatic retrosynthesis of L-TFB-TBOA (2a).

To enable efficient multigram-scale (see SI) synthesis of 1, we first optimized the previously used procedure for the small-scale (150 mg) synthesis of **1**.^{11b} The addition of benzyl alcohol to 3 yields a mixture of *cis* and *trans* product isomers (Scheme 2A, step a). After ester hydrolysis of this isomeric mixture (step b), we purified the trans-2-benzyloxyfumaric acid (6) by recrystallization (37% yield over two steps). This provided a higher yield of 6 when compared to the previously reported column chromatography method for isomer separation.^{11b} In addition, the efficiency of the methylaspartate ammonia lyase (MAL-L384A)-catalyzed amination of 6 (step c) was enhanced by using NH₃ (instead of NH₄Cl) and pH 9.5 (instead of pH 9.0), leading to >98% conversion and affording product **1** in 80\% isolated yield.

Organic & Biomolecular Chemistry Accepted Manuscript

View Article Online

Starting from compound 1, the synthesis of key intermediate 4 was achieved in three successive reactions (steps d-f in Scheme 2B). Diesterification of 1 with SOCl₂ in dry methanol, followed by Boc-protection, delivered compound 8 without the need for purification. Hydrogenolysis of 8 using HCOONH₄/Pd gave 4 in excellent yield (71% over three steps).¹² Notably, exhaustive esterification of both carboxyl groups of compound 1 needs high $SOCl_2$ concentration (10 equivalents) under reflux, while mono-esterification of the C4-carboxyl group of 1 could be easily accomplished under ambient conditions with one equivalent of SOCl₂. Another route (steps g-i in Scheme 2B) for preparing the chiral building block 4 was also designed by rearranging the three reactions described above. We initiated the synthetic procedure with debenzylation of 1, which provided 3-hydroxyaspartic acid (9), and which was followed by esterification and Boc-protection to afford 4 in three steps with 73% overall yield.



Scheme 2. Chemoenzymatic synthesis of L-TBOA (1) and chiral building block 4. Reagents and conditions: a) BnOH, DABCO, DCM, rt, 4 h; b) NaOH (2 M), reflux, 2h, then HCl (1 M), two-step yield after recrystallization was 37%; c) MAL-L384A (0.01 mol%), 5 M NH₃/NH₄Cl, 20 mM MgCl₂, pH = 9.5, 24 h, conversion >98%,

View Article Online isolated yield 80%; d) SOCl₂, MeOH, reflux, 6 h; e) di-*tert*-butyl dicarbonate OEEA9/C7OB00305F DCM, rt, 24 h; f) Pd/C, HCOONH₄, MeOH, reflux, 45 min, 71% for 3 steps; g) Pd/C, HCOONH₄, MeOH, reflux, 45 min; h) SOCl₂, MeOH, reflux, 6 h; i) di-tert-butyl DIEA, DCM, 24 h. 73% for 3 DABCO, dicarbonate, rt, steps. 1,4-diazabicyclo[2.2.2]octane; DIEA, *N*,*N*-diisopropylethylamine; DCM, dichloromethane.

With chiral building block **4** in hand, the synthesis of target molecule L-TFB-TBOA (**2a**) could be accomplished through *O*-alkylation, followed by global deprotection (steps a-c in Scheme 3). This strategy provides a general synthesis route towards derivatives of L-*threo*-3-hydroxyaspartic acid, including valuable analogs of L-TBOA and L-TFB-TBOA. To facilitate efficient *O*-alkylation, which is effected by a nucleophilic substitution reaction of **4** and **5** (for synthesis details, see SI), the strong base NaH was used to deprotonate the hydroxyl group of **4**. A low temperature (-20 °C) was needed to avoid epimerization, and the desired compound **11** (i.e., globally protected **2a**) was obtained with an isolated yield of 45%. Subsequently, global deprotection of **11** was conducted via treatment with TFA and followed by hydrolysis with LiOH, providing the desired final product **2a** (L-TFB-TBOA hydrochloride) in a yield of 59% over two deprotection steps.

As anticipated, product 2a was identified as the desired *threo* isomer (*de* >98%) by comparison of its ¹H-NMR signals and *J*-coupling values to those of an authentic standard (commercially available L-TFB-TBOA) and chemically synthesized DL-*threo* and DL-*erythro* stereoisomers (Table S1). To determine the absolute configuration of product 2a, chiral HPLC analysis was conducted by using the

Organic & Biomolecular Chemistry Accepted Manuscrip

/iew Article Online

authentic standard L-TFB-TBOA and chemically synthesized DL-TFB-TBOA^{DCCOBO0303F} as reference molecules. This analysis revealed that the chemoenzymatically produced **2a** is present as a single enantiomer with exclusively the L-*threo* configuration (*ee* >99%, Table 1). The usefulness of our synthesis strategy was further demonstrated by the preparation of optically pure **2a** at multigram-scale (2.1 g; see SI). In addition, two novel optically pure L-TFB-TBOA analogs, **2b** (*o*-CF₃, *de* >98%, *ee* >99%) and **2c** (*m*-CF₃, *de* >98%, *ee* >99%), were prepared using this newly developed methodology (Table 1).



Scheme 3. Synthesis of L-TFB-TBOA and its derivatives. Reagents and conditions: a) ArCH₂Br (5, see SI), NaH, DMF, -20 °C, 4 h, 42% - 50%; b) TFA/DCM (2:5, v/v), 0 °C, 1.5 h; c) THF/H₂O (1:1, v/v), LiOH, rt, 2 h, then HCl (1 M), 38% - 59%; d) 3-nitrobenzylbromide, NaH, DMF, -20 °C, 4 h, 61%; e) Pd/C, H₂, MeOH, 25 min, 92%; f) acyl chlorides (14, see SI), TEA, DCM, rt, 2 h, 51% - 65%. TFA, trifluoroacetic acid; THF, tetrahydrofuran; TEA, trimethylamine.

Medicinal chemists are highly interested in building a large collection of *meta*-substituted analogs of L-TBOA to screen for potent and selective inhibitors of

/iew Article Online

EAAT subtypes.^{6b, 13} In order to rapidly construct a library of L-TBOA analogs with ^{(C7OB003064} various groups at the *meta*-position, we envisioned that intermediate **13**, with a free *m*-NH₂ group, would be a convenient precursor for fast structural diversification by applying combinatorial chemistry methodologies. The synthesis of compound **13** was accomplished through a nucleophilic substitution reaction between **4** and *m*-nitrobenzylbromide, yielding **12**, followed by conversion of the nitro group to an amino group with Pd/C/H₂, in a yield of 59% over two steps. To demonstrate the utility of intermediate **13**, we synthesized two L-TFB-TBOA analogs (**16a-b**) with a longer alkyl spacer between the two phenyl rings (Scheme 3). Compound **15** was formed via amidation of the amino group of **13** with acyl chloride **14**. Target products **16a** and **16b** were obtained in optically pure form after two steps of deprotection (Table 1).

Conclusion

In conclusion, we have managed to construct the complex amino acid L-TFB-TBOA using only 9 steps with 6% overall yield, starting from commercially available dimethyl acetylenedicarboxylate. Compared with the previously reported 20-step synthesis of L-TFB-TBOA, this is a dramatic reduction in step count with fewer than half the steps. This chemoenzymatic synthesis methodology can be easily up-scaled to multigram-scale and gives convenient access to enantiopure derivatives of L-TBOA and L-TFB-TBOA

Organic & Biomolecular Chemistry Accepted Manuscrip

View Article Online DOI: 10.1039/C7OB00305F

OH. $de[\%]^a$ *ee* [%]^{*b*} Entry No. R Absolute n configuration 1 >99 $(2S, 3S)^{c}$ 2a p-CF₃ 0 >98 2 2bo-CF₃ 0 >98 >99 (2S, 3S)3 m-CF₃ >98 >99 (2S, 3S)**2c** 0 4 p-CF₃ >98 >99 (2S, 3S)16a 1 5 p-CF₃ 2 >98 >99 (2S, 3S)16b

 Table 1. Absolute configuration of chemoenzymatically obtained L-TFB-TBOA and its derivatives.

NH₃CI

^{*a*} Diastereomeric excess (*de*) was determined by ¹H NMR. ^{*b*} Enantiomeric excess (*ee*) was determined by chiral HPLC. ^{*c*} Absolute configuration was determined unambiguously by comparison of ¹H NMR, chiral HPLC and optical rotation data to those of an authentic sample of L-TFB-TBOA (2*S*,3*S*).

Acknowledgements

This research was financially supported by the Netherlands Organisation for Scientific Research (KIEM grants 731.013.110 and 731.015.108). Haigen Fu and Jielin Zhang acknowledge funding from the China Scholarship Council. The authors thank Dr. Marianne de Villiers for insightful discussions.

Keywords

Organic & Biomolecular Chemistry Accepted Manuscript

Asymmetric synthesis, biocatalysis, amino acids, inhibitor, glutamate transport.

Experimental Section

For detailed experimental procedures and characterization of compounds, see supplementary information.

Notes and References

- (a) N. C. Danbolt, *Prog. Neurobiol.* 2001, 65, 1; (b) P. Beart, R. O'shea, *Br. J. Pharmacol.* 2007, 150, 5; (c) R. J. Vandenberg, R. M. Ryan, *Physiol. Rev.* 2013, 93, 1621; (d) A. A. Jensen, C. Fahlke, W. E. Bjørn-Yoshimoto, L. Bunch, *Curr. Opin. Pharmacol.* 2015, 20, 116.
- 2 E. E. Benarroch, *Neurology* 2010, **74**, 259.
- 3 A. V. Tzingounis, J. I. Wadiche, *Nat. Rev. Neurosci.* 2007, **8**, 935.
- L. Bunch, M. N. Erichsen, A. A. Jensen, *Expert. Opin. Ther. Targets.* 2009, 13, 719.
- (a) B. Lebrun, M. Sakaitani, K. Shimamoto, Y. Yasuda-Kamatani, T. Nakajima, J. Biol. Chem. 1997, 272, 20336; (b) K. Shimamoto, B. Lebrun, Y. Yasuda-Kamatani, M. Sakaitani, Y. Shigeri, N. Yumoto, T. Nakajima, Mol. Pharmacol. 1998, 53, 195; (c) K. Shimamoto, Y. Shigeri, Y. Yasuda-Kamatani, B. Lebrun, N. Yumoto, T. Nakajima, Bioorg. Med. Chem. Lett. 2000, 10, 2407.
 - (a) K. Shimamoto, R. Sakai, K. Takaoka, N. Yumoto, T. Nakajima, S. G.

6

Organic & Biomolecular Chemistry Accepted Manuscrip

Amara, Y. Shigeri, *Mol. Pharmacol.* 2004, **65**, 1008; (b) K. Shimamoto, *Chem. Rec.* 2008, **8**, 182; (c) S. Tsukada, M. Iino, Y. Takayasu, K. Shimamoto, S.
Ozawa, *Neuropharmacology* 2005, **48**, 479.

- 7 K. Shimamoto, *Patent* 2003, WO2003/000698 A000691.
- 8 M. Leuenberger, A. Ritler, A. Simonin, M. A. Hediger, M. Lochner, ACS Chem. Neurosci. 2016, 7, 534.
- D. Jabaudon, K. Shimamoto, Y. Yasuda-Kamatani, M. Scanziani, B. Gähwiler,
 U. Gerber, *Proc. Natl. Acad. Sci. U.S.A.* 1999, 96, 8733.
- (a) D. L. Boger, R. J. Lee, P.-Y. Bounaud, P. Meier, J. Org. Chem. 2000, 65, 6770;
 (b) L. Harris, S. P. Mee, R. H. Furneaux, G. J. Gainsford, A. Luxenburger, J. Org. Chem. 2010, 76, 358;
 (c) Y. Jiang, X. Chen, Y. Zheng, Z. Xue, C. Shu, W. Yuan, X. Zhang, Angew. Chem. Int. Ed. 2011, 50, 7304;
 (d) A. C. Willis, M. D. McLeod, J. Org. Chem. 2012, 77, 8480;
 (e) D.-F. Lu, C.-L. Zhu, Z.-X. Jia, H. Xu, J. Am. Chem. Soc. 2014, 136, 13186.
- (a) H. Raj, W. Szymański, J. de Villiers, H. J. Rozeboom, V. P. Veetil, C. R. Reis, M. de Villiers, F. J. Dekker, S. de Wildeman, W. J. Quax, A.-M. W. H. Thunnissen, B. L. Feringa, D. B. Janssen, G. J. Poelarends, *Nat. Chem.* 2012, 4, 478; (b) J. de Villiers, M. de Villiers, E. M. Geertsema, H. Raj, G. J. Poelarends, *ChemCatChem* 2015, 7, 1931.
- 12 T. Bieg, W. Szeja, *Synthesis* 1985, **1985**, 76.
- J. C. Hansen, W. E. Bjørn-Yoshimoto, N. Bisballe, B. Nielsen, A. A. Jensen, L. Bunch, *J. Med. Chem.* 2016, **59**, 8771.

TOC text

Rapid route to L-TFB-TBOA: Using only nine chemical transformations, we have managed to construct the complex amino acid L-TFB-TBOA starting from commercially available dimethyl acetylenedicarboxylate. Compared with the previously reported 20-step synthesis of L-TFB-TBOA, this is a dramatic reduction in step count with fewer than half the steps. This methodology can be easily upscaled to multigram-scale and gives convenient access to enantiopure derivatives of L-TFB-TBOA.

TOC graphic

